Patel Suchit H, Rimner Andreas, Cohen Roger B
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.
Division of Hematology-Oncology, Perelman Center for Advanced Medicine, Philadelphia, USA.
Transl Lung Cancer Res. 2017 Apr;6(2):186-195. doi: 10.21037/tlcr.2017.03.04.
Recent work with immunotherapy has shown promising results with treatment of several solid malignancies, and there are several reports of good systemic responses with the combination of immunotherapy and radiation therapy (RT), most notably in advanced melanoma. Given the rapid increase in the use of checkpoint blockade as well as anti-tumor vaccines, we review here the preclinical rationale and ongoing clinical work in combining immunotherapy with RT for small cell lung cancer (SCLC) and thymic tumors. While there are several reports of promising results with the combination of immunotherapy and conventional systemic treatment, we focus here on the ongoing clinical studies that combine immunotherapy with RT, and highlight the emerging data for this multimodality approach as well as key preclinical and clinical issues that remain to be addressed. With regards to SCLC, trials exploring to the combination of immunotherapy and RT are already ongoing, but clinical studies for this combination in thymoma are lacking.
近期免疫疗法的研究在多种实体恶性肿瘤的治疗中显示出了有前景的结果，并且有若干关于免疫疗法与放射治疗（RT）联合应用取得良好全身反应的报道，最显著的是在晚期黑色素瘤中。鉴于检查点阻断以及抗肿瘤疫苗的使用迅速增加，我们在此回顾将免疫疗法与RT联合用于小细胞肺癌（SCLC）和胸腺肿瘤的临床前理论依据及正在进行的临床研究。虽然有若干关于免疫疗法与传统全身治疗联合应用取得有前景结果的报道，但我们在此聚焦于将免疫疗法与RT联合的正在进行的临床研究，并突出这种多模式方法的新出现的数据以及仍有待解决的关键临床前和临床问题。关于SCLC，探索免疫疗法与RT联合应用的试验已经在进行，但在胸腺瘤中针对这种联合应用的临床研究尚缺乏。
